Form D — X4 Pharmaceuticals, Inc
0001470831-25-000145 · filed 2025-08-25
Offering
- Industry
- Biotechnology
- Exemptions
- 06b
- Total offering
- $84,999,985
- Total sold
- $84,999,985
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- X4 Pharmaceuticals, Inc
- CIK
- 1501697
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- —
- Address
- 61 NORTH BEACON STREET
BOSTON, MA 02134 - Phone
- 857-529-8300
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Mark Baldry · Executive OfficerBOSTON, MA Find on LinkedIn ↗
-
Adam Craig · Executive OfficerBOSTON, MA Find on LinkedIn ↗
-
John Volpone · Executive OfficerBOSTON, MA Find on LinkedIn ↗
-
Christophe Arbet-Engels · Executive OfficerBOSTON, MA Find on LinkedIn ↗
-
Mary DiBiase · Executive OfficerBOSTON, MA Find on LinkedIn ↗
-
David Kirske · Executive OfficerBOSTON, MA Find on LinkedIn ↗
-
Gary J. Bridger · DirectorBOSTON, MA Find on LinkedIn ↗
-
Francoise De Craecker · DirectorBOSTON, MA Find on LinkedIn ↗
-
Murray W. Stewart · DirectorBOSTON, MA Find on LinkedIn ↗
-
Michael S. Wyzga · DirectorBOSTON, MA Find on LinkedIn ↗
View original on SEC EDGAR.